Thousand Oaks, CA, United States of America

Victor J Cee

This inventor holds 37 USPTO granted patents and 21 published patent applications, plus 7 CIPO patents and 21 EPO patents, primarily in KRAS Inhibitors. Top assignees: Amgen Inc., Epix Pharmaceuticals, Inc., Teijin Pharma Limited. Active years: 2009-2026.

USPTO Granted Patents = 37 (Patent Applications = 21)

% Patents Active = 81.1

CIPO Patents = 7 (Patent Applications = 12)

EPO Patents = 21 (Patent Applications = 27)

Average Co-Inventor Count = 8.1

ph-index = 13

Forward Citations = 525(Granted Patents)

Location History:

Mansfield, MA (US) (2010 - 2011)
Thousand Oaks, CA (US) (2009 - 2024)

Company Filing History:

Epix Pharmaceuticals, Inc.

patents

1 out of 126

Teijin Pharma Limited

patents

where one patent can have more than one assignee

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

KRAS G12C Inhibitors

Protein Kinase Modulators

S1P Receptor Compounds

Aurora Kinase Modulators

Piperazine Derivatives

Amides

Pyrazole Compounds

Bicyclic Compounds

Heteroaryl-Substituted Alkynes

Multi-Cyclic Compounds

PIM Inhibitors

mTOR Inhibitors

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12715868 - SMARCA2-VHL degraders (2026-08-25),

2. 12583854 - KRAS G12C INHIBITORS AND METHODS OF USING THE SAME (2026-03-24),

3. 12440491 - KRAS G12C inhibitors and methods of using the same (2025-10-14),

4. 12083121 - Substituted piperazines as KRAS G12C inhibitors (2024-09-10),

5. 11993597 - Inhibitors of KRAS G12C and methods of using the same (2024-05-28),

6. 11905281 - KRAS G12C inhibitors and methods of using the same (2024-02-20),

7. 11766436 - KRAS G12C inhibitors and methods of using the same (2023-09-26),

8. 11426404 - [object Object] (2022-08-30),

9. 11306087 - Inhibitors of KRAS G12C and methods of using the same (2022-04-19),

10. 11285156 - Substituted piperazines as KRAS G12C inhibitors (2022-03-29),

11. 11285135 - KRAS G12C inhibitors and methods of using the same (2022-03-29),

12. 11096939 - KRAS G12C inhibitors and methods of using the same (2021-08-24),

13. 11090304 - KRAS G12C inhibitors and methods of using the same (2021-08-17),

14. 11053226 - KRAS G12C inhibitors and methods of using the same (2021-07-06),

15. 11045484 - KRAS G12C inhibitors and methods of using the same (2021-06-29),

Title: Victor J Cee: Innovator in Cancer Therapeutics

Introduction

Victor J Cee, located in Thousand Oaks, California, is a prominent inventor known for his contributions to cancer research and therapeutics. With an impressive portfolio of 34 patents, his work primarily focuses on the development of inhibitors targeting specific cancer-related proteins.

Latest Patents

Among his latest innovations are two significant patents concerning substituted piperazines as inhibitors of KRAS G12C. These patents detail compositions and methodologies for utilizing these inhibitors in treating various disorders, including pancreatic, colorectal, and lung cancers. The focus on KRAS G12C reflects a targeted approach in cancer therapy, which aims to improve patient outcomes through innovative drug development.

Career Highlights

Victor's professional journey includes key positions at notable companies in the pharmaceutical industry. He has worked with Amgen Inc., a leader in biotechnology, and Epix Pharmaceuticals, Inc., where his research and innovative contributions have significantly advanced the field. His extensive experience and expertise underscore his role as a valuable innovator in cancer treatment.

Collaborations

Throughout his career, Victor has collaborated with distinguished colleagues, including Brian Alan Lanman and Anthony B Reed. These partnerships have fostered a collaborative environment that contributes significantly to the development of groundbreaking therapeutic solutions.

Conclusion

Victor J Cee’s dedication to innovation in cancer therapeutics, coupled with his extensive patent portfolio, showcases his impactful contributions to the medical field. His ongoing research promises to pave the way for novel treatments that could greatly benefit patients suffering from various types of cancer.